More on BCRX

- Summary
- Chart
- Profile
- Historical


- Earnings (+42.1% Growth)
- Ratings (8.3 Score)
- Holders
- FDA Archive


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (2/21/24)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

BCRX Balance Sheet

Click line-items for a historical chart and %
Cash and cash equivalents 35.39M
Restricted cash 1.51M
Marketable securities 17.43M
Receivables from collaborations
Interest reserve
Inventories 2.23M
Prepaid expenses and other current assets 2.01M
Deferred collaboration expense 98K
Total current assets 64.63M
Marketable securities 14.37M
Furniture and equipment, net 10.1M
Deferred collaboration expense 214K
Other assets 2.19M
Total assets 91.5M
Liabilities and Stockholders' Equity
Accounts payable 2.76M
Accrued expenses 10.78M
Interest payable 7.56M
Deferred collaboration revenue 2.28M
Total current liabilities 51.52M
Deferred rent 265K
Deferred collaboration revenue 8.48M
Foreign currency derivative
Non-recourse notes payable
Commitments and contingencies
Stockholders' equity:
Preferred stock: 5,000 shares authorized; none issued and outstanding 0
Common stock, $.01 par value: shares authorized - 95,000; shares issued and outstanding - 45,150 in 2011 and 44,959 in 2010 738K
Additional paid-in capital
Accumulated other comprehensive income 22K
Accumulated deficit -561.56M
Total stockholders' equity 3.99M
Total liabilities and stockholders' equity 91.5M